<DOC>
	<DOCNO>NCT01763385</DOCNO>
	<brief_summary>This project aim explore non-increased-intracranial-pressure symptomatic brain metastasis NSCLC , OS secondary brain radiotherapy recurrence Erlotinib good Erlotinib concurrent brain radiotherapy . Treatment group treat Erlotinib brain tumor progression , give brain radiotherapy , continue take Erlotinib till extracranial lesion progression . Control group Erlotinib concurrent brain radiotherapy , continue take Erlotinib radiotherapy recurrence termination reason .</brief_summary>
	<brief_title>Erlotinib With Concurrent Brain Radiotherapy Secondary Brain Radiotherapy After Recurrence With Erlotinib NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Over age 18 year old ; 2 . Tissue cell pathological diagnosis NSCLC ; 3 . Brain CT MR validate BM ; 4 . Nonincreasedintracranialpressure symptomatic BM ; 5 . Have n't receive TKI target treatment ; 6 . Have n't receive brain radiotherapy ; 7 . Patients initial treatment detect EGFR mutation ; 8 . Expected survival 6 month ; 9 . KPS le 70 , KPS le 70 caused paralysis due recent brain metastasis ; 10 . Liver kidney function requirement : SGOT/SGPT≦2.5 time upper limit , Total bilirubin≦1.5 time upper limit , serum Creatinine≦1.5 time upper limit ; 11 . Routine blood test requirement : WBC≧3.0×109/L , NE≧1.8×109/L , PLT≧90×109/L，no requirement Hb ; 12 . Blood glucose requirement : within normal range , diabetic patient receive treatment glucose control steady state ; 13 . Female patient childbearing age : HCG ( ) ; 14 . Patients sign inform Consent . 1 . Those Erlotinib drug allergy ; 2 . Those mathematical understanding simple life question , `` walking '' , difficult doctor communicate ; 3 . Those without guardian family ; 4 . Those abnormal routine blood test , liver kidney function , blood glucose beyond boundary difficult correct 2 week ; 5 . Those unstable medical status ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction ( within one year treatment initiation ) , severe arrhythmia , liver , kidney metabolic disease require drug therapy ) ; 6 . Those disease , neurological metabolic dysfunction , physical examination laboratory test result show study drug may increase risk treatmentrelated complication ; 7 . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>brain radiotherapy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>brain metastasis</keyword>
</DOC>